Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 13;9:82. doi: 10.3389/fphar.2018.00082

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Fu, Li, Luo, Li, Liu and Gui.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Knockdown of MIAT sensitizes PC9 and PC9/R cells to gefitinib. (A) qRT-PCR analysis for MIAT in PC9 and PC9/R cells after transfection with MIAT siRNA or negative control. (B) CCK-8 assay was used to determine the IC50 in PC9 and PC9/R cells (PC9 vs. PC9/R: 29.05 vs. 62.61 μM). (C) CCK-8 assay was used to determine the change of IC50 in PC9/R cells after knockdown of MIAT (siMIAT vs.NC: 38.2 vs. 60.2 μM). (D) Colony formation assay was used to determine the cell growth after knockdown of MIAT and gefitinib treatment. (E) Flow cytometry was used to measure cell apoptosis after knockdown of MIAT and gefitinib treatment. (F) Western blot analysis for apoptosis marker Bcl-2, Bax and cleaved caspase 3 after knockdown of MIAT and gefitinib treatment. ^∗P < 0.05, ^∗∗P < 0.01.